Department of Orthopaedic Surgery and Traumatology, Cantonal Hospital, St. Gallen, Rorschacherstreet 95, 9007, St. Gallen, Switzerland.
Department of Medical Oncology and Haematology, Cantonal Hospital, St. Gallen, Switzerland.
Knee Surg Sports Traumatol Arthrosc. 2019 Apr;27(4):1182-1188. doi: 10.1007/s00167-018-5030-3. Epub 2018 Jun 28.
This study was designed to determine whether perioperative supplementation of vitamin C (VC) improves range of motion (ROM) and reduces the risk of arthrofibrosis (AF) following total knee arthroplasty (TKA).
Ninety-five patients undergoing TKA were randomized to either oral VC (1000 mg daily) or placebo for 50 days (48 VC group, 47 placebo group). The effect of VC supplementation was tested on ROM, AF, WOMAC, FJS-12, and VC plasma concentrations (VCc). VCc were analyzed in both patient groups before surgery, 4 and 7 days after surgery.
ROM at 1 year was not different between study groups. The prevalence of AF was 5 of 48 (10.4%) in the VC group compared to 11 of 47 (23.4%) in the placebo group (p = 0.09). VCc decreased post-operatively in the placebo group (49-12 µmol/l on day 7, p < 0.001), but not in the VC group (53-57 µmol/l). Patients with a perioperative drop of VCc ≥ 30 µmol/l developed significantly more AF at 1 year compared to patients with a VCc drop of < 30 µmol/l (p = 0.007).
TKA results in VC depletion. Perioperative VC supplementation prevents VCc drop in most patients undergoing TKA and may lower the incidence of AF. The clinical relevance of this study is that VC supplementation seems to be a cheap and safe adjunct to improve functional outcome after TKA.
I.
The study was registered at the ISRCTN registry with study ID ISRCTN40250576.
本研究旨在确定围手术期补充维生素 C(VC)是否能改善全膝关节置换术后的关节活动度(ROM)并降低关节纤维强直(AF)的风险。
95 例行 TKA 的患者被随机分为口服 VC(每天 1000mg)或安慰剂组,共 50 天(48 例 VC 组,47 例安慰剂组)。在 ROM、AF、WOMAC、FJS-12 和 VC 血浆浓度(VCc)方面测试了 VC 补充的效果。在手术前、手术后 4 天和 7 天对两组患者的 VCc 进行了分析。
1 年时两组的 ROM 无差异。VC 组中 AF 的发生率为 5/48(10.4%),而安慰剂组为 11/47(23.4%)(p=0.09)。安慰剂组术后 VCc 下降(第 7 天 49-12µmol/l,p<0.001),而 VC 组则没有(53-57µmol/l)。围手术期 VCc 下降≥30µmol/l 的患者在 1 年时发生 AF 的明显多于 VCc 下降<30µmol/l 的患者(p=0.007)。
TKA 导致 VC 耗竭。围手术期 VC 补充可预防大多数接受 TKA 的患者的 VCc 下降,并可能降低 AF 的发生率。本研究的临床意义在于,VC 补充似乎是一种廉价且安全的辅助手段,可改善 TKA 后的功能结局。
I。
该研究在 ISRCTN 登记处注册,研究 ID 为 ISRCTN40250576。